<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Regulatory</title>
	<atom:link href="http://www.tapanray.in/tag/regulatory/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s Healthcare Is Still Not Patient-Friendly &#8211; Why ‘Patient Centricity’ in Pharma Remains a Slogan More Than a System</title>
		<link>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system</link>
		<comments>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/#comments</comments>
		<pubDate>Sun, 23 Nov 2025 14:17:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[friendly]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[not patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[slogan]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11004</guid>
		<description><![CDATA[Executive Summary: Despite constant advocacy around “patient centricity,” India’s healthcare ecosystem &#8211; from pharma to hospitals &#8211; continues to show deep structural gaps. Safety failures, unethical marketing practices, opaque pricing, and hospital-level exploitation still undermine patient trust. This article uses illustrative &#8230; <a href="http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>When ‘Vikshit Bharat’ Rings Hollow: A Tragedy That Exposes India’s Uneven Progress</title>
		<link>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress</link>
		<comments>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/#comments</comments>
		<pubDate>Fri, 10 Oct 2025 11:25:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cough]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[hollow]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rings]]></category>
		<category><![CDATA[syrup]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tragedy]]></category>
		<category><![CDATA[Vikshit Bharat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10978</guid>
		<description><![CDATA[India’s vision of Vikshit Bharat promises inclusive growth and modern progress. Yet, when children die from contaminated cough syrup, that dream rings hollow. This article asks the hard question: can a nation truly be “developed” when its weakest citizens still fall victim &#8230; <a href="http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India&#8217;s Pharmacy Frontier: Blurring Lines and Battling for Balance</title>
		<link>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-pharmacy-frontier-blurring-lines-and-battling-for-balance</link>
		<comments>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/#comments</comments>
		<pubDate>Fri, 20 Jun 2025 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[e-pharmacy]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[retail]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10921</guid>
		<description><![CDATA[As we witness, India&#8217;s pharmaceutical landscape is undergoing a profound transformation, driven by technological advancements and shifting consumer preferences. The traditional brick-and-mortar retail pharmacy, a familiar fixture in every neighborhood, now faces a formidable challenger: the burgeoning online pharmacy sector. &#8230; <a href="http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Unseen Terror: Fake Drugs Claim More Lives Than Terrorism in India</title>
		<link>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india</link>
		<comments>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/#comments</comments>
		<pubDate>Thu, 15 May 2025 07:43:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Terror]]></category>
		<category><![CDATA[terrorism]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10896</guid>
		<description><![CDATA[In May 2025, the Union Health Ministry acknowledged in a response to the Lok Sabha that over 7,500 drug samples failed quality tests across India in the previous year, with spurious drugs reported from nearly every major state. The admission, &#8230; <a href="http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Failures Are Still Risking Patient Lives</title>
		<link>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-failures-are-still-risking-patient-lives</link>
		<comments>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/#comments</comments>
		<pubDate>Sun, 06 Oct 2024 06:37:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[lives]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[risking]]></category>
		<category><![CDATA[self-regulation]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[sustainabilitycompanies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TechnologyAwareness]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10880</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry faces renewed scrutiny as the Drug Controller General of India (DCGI) flagged numerous substandard drugs in September 2024. At the same time, an October 02, 2024, Business Standard report highlights an ongoing crackdown on such drugs by regulators. This article explores &#8230; <a href="http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Game-Changing Non-Covid Drug Approval In the Pandemic Milieu</title>
		<link>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu</link>
		<comments>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/#comments</comments>
		<pubDate>Mon, 11 Oct 2021 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[designation]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insuline]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[milieu]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Semglee]]></category>
		<category><![CDATA[superior]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10595</guid>
		<description><![CDATA[Amid high decibel deliberations on Covid-19 pandemic, something similar to groundbreaking happened &#8211; involving Biosimilar drugs, in just a couple of months ago. On July 28, 2021, in the Eldorado of the pharma industry, the US-FDA approved  the first ‘interchangeable’ biosimilar drug, &#8230; <a href="http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unfettered ‘Access To Drug Innovation’ &#8211; An Oxymoron?</title>
		<link>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unfettered-access-to-drug-innovation-an-oxymoron</link>
		<comments>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/#comments</comments>
		<pubDate>Mon, 06 Sep 2021 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[customer. consumer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[off-patent]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[property< India]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[undermining]]></category>
		<category><![CDATA[unfettered]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10582</guid>
		<description><![CDATA[The mass paranoia, as it were, over Covid pandemic has now started fading with drug regulators’ ‘emergency approval’ of several Covid -19 vaccines, and its free of cost access to all, generally in most countries. As the endgame of the pandemic, &#8230; <a href="http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India Not To Vaccinate All For Covid Control: Upsides And Unknowns</title>
		<link>http://www.tapanray.in/india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns</link>
		<comments>http://www.tapanray.in/india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns/#comments</comments>
		<pubDate>Mon, 07 Dec 2020 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[authorization]]></category>
		<category><![CDATA[citizen]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[emergency-use]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[group]]></category>
		<category><![CDATA[immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Moderna]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Oxford]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[Prime Minister]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sputnik V]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[U.K]]></category>
		<category><![CDATA[unknowns]]></category>
		<category><![CDATA[upsides]]></category>
		<category><![CDATA[Vaccinate]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[work in progress]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10355</guid>
		<description><![CDATA[With 9.46 million cases and 137,621 deaths, India has currently the world’s second-highest number of coronavirus infections, behind only the United States, reported Reuters on December 01, 2020. Fathoming seriousness of rapidly unfolding Covid induced all round disruptions across the nation, on &#8230; <a href="http://www.tapanray.in/india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Quality Imbroglio And ‘Culture of Bending Rules’ in India</title>
		<link>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-quality-imbroglio-and-culture-of-bending-rules-in-india</link>
		<comments>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/#comments</comments>
		<pubDate>Mon, 27 May 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bending]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[culpable]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[Culture of Bending Rules]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[non-branded]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9539</guid>
		<description><![CDATA[“Bottle Of Lies Exposes The Dark Side Of The Generic-Drug Boom” &#8211; re-emphasized the book, released in May 2019.  This confirms, the raging debate on the questionable quality of many generic drugs manufactured in India and involving several top domestic pharma companies, &#8230; <a href="http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is India A Success Story With Biosimilar Drugs?</title>
		<link>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-india-a-success-story-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 25 Feb 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9422</guid>
		<description><![CDATA[How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse &#8211; but the initiative is not a current one. This journey commenced decades ago &#8230; <a href="http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
